Sorrento Therapeutics, Inc. (SRNE): Business Model Canvas

Key Partnerships

Sorrento Therapeutics, Inc. understands the importance of forming strong partnerships to advance its innovative biotech solutions. The company has established key partnerships with various entities to strengthen its position in the industry and drive growth.

• Sorrento Therapeutics has collaborated with several biotech companies to leverage their expertise and resources in developing new therapies and technologies. These partnerships allow Sorrento Therapeutics to access complementary capabilities and expand its research and development efforts.

• By forming research alliances with top universities, Sorrento Therapeutics gains access to cutting-edge research and academic expertise. These partnerships enable the company to explore new scientific avenues and stay at the forefront of innovation within the biotech industry.

• Sorrento Therapeutics has established partnerships with clinical trial centers to conduct advanced trials for its products. These collaborations help the company navigate the complex regulatory landscape and accelerate the development and commercialization of its therapies.

• To reach a broader market, Sorrento Therapeutics has entered into strategic agreements with pharmaceutical distributors. These partnerships enable the company to efficiently distribute its products to healthcare providers and patients, increasing accessibility and visibility in the market.

Key Activities

Sorrento Therapeutics, Inc. is primarily focused on conducting research and development of new therapies to address unmet medical needs in various disease areas. The company invests heavily in innovative drug discovery and development processes to create novel treatments for patients.

• Research and Development: Sorrento Therapeutics allocates a significant portion of its resources towards the research and development of potential therapeutic candidates. This involves a multidisciplinary approach that includes molecular biology, immunology, and medicinal chemistry.
• Clinical Trials Management: Once a potential drug candidate has shown promising preclinical results, Sorrento Therapeutics initiates clinical trials to assess the safety and efficacy of the therapy in humans. The company is responsible for designing and executing these trials in accordance with regulatory guidelines.
• Marketing and Commercialization: Upon successful completion of clinical trials, Sorrento Therapeutics focuses on the marketing and commercialization of approved drugs. This includes creating strategic partnerships with distributors, healthcare providers, and payers to ensure widespread availability of their products.
• Ongoing Innovation: Sorrento Therapeutics is committed to continuous innovation in drug delivery systems to improve the efficacy, safety, and convenience of their therapies. The company explores new technologies and methods to enhance the delivery of therapeutic compounds to target tissues.

By engaging in these key activities, Sorrento Therapeutics strives to bring breakthrough therapies to patients and make a meaningful impact in the field of healthcare.

Key Resources

Intellectual property including patents: Sorrento Therapeutics, Inc. (SRNE) has a robust portfolio of intellectual property that includes various patents related to their innovative therapies and technologies. These patents provide the company with a competitive advantage in the market and protect their innovations from being duplicated by competitors.

Scientific and research staff: SRNE employs a team of highly qualified and experienced scientific and research staff who are instrumental in developing new therapies and conducting cutting-edge research. These experts bring a wealth of knowledge and expertise to the company, driving innovation and advancement in the field of biotechnology.

State-of-the-art laboratory facilities: SRNE boasts state-of-the-art laboratory facilities that are equipped with the latest technologies and equipment necessary for conducting research, testing, and development of new therapies. These facilities play a crucial role in the company's ability to innovate and bring new therapies to market.

Regulatory expertise: SRNE has a team of regulatory experts who are well-versed in navigating the complex regulatory landscape of the biotechnology industry. This expertise is crucial for ensuring that the company's therapies comply with regulatory requirements and gain approval from regulatory agencies.

• Intellectual property including patents
• Scientific and research staff
• State-of-the-art laboratory facilities
• Regulatory expertise

Value Propositions

Sorrento Therapeutics, Inc. (SRNE) is dedicated to providing innovative oncology treatment solutions that address unmet medical needs in the field of cancer treatment. Our value proposition lies in our ability to develop therapies that not only reduce side effects but also enhance drug efficacy, ultimately improving the quality of life for cancer patients.

One of our key value propositions is our commitment to personalized medicine in cancer treatment. By leveraging advanced technologies such as antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T-cell therapy, we are able to tailor treatments to the specific genetic mutations of an individual's cancer, thereby increasing the likelihood of a successful outcome.

Additionally, we strive to stay at the forefront of scientific research and innovation in the oncology space, constantly exploring new avenues for treatment and pushing the boundaries of what is possible in cancer therapy. This dedication to cutting-edge science and technology sets us apart from our competitors and allows us to offer unique solutions to the challenges faced by oncology patients.

• Innovative oncology treatment solutions: We develop novel therapies that target cancer cells with precision, minimizing harm to healthy tissues.
• Focus on unmet medical needs: Our research is focused on areas of oncology where current treatments are insufficient, providing new options for patients with limited choices.
• Reduced side effects and enhanced drug efficacy: By optimizing our treatments, we are able to minimize side effects while maximizing the effectiveness of our drugs.
• Commitment to personalized medicine in cancer treatment: Our approach is to tailor treatments to the specific genetic makeup of each patient, increasing the likelihood of a successful outcome.

Customer Relationships

Sorrento Therapeutics, Inc. (SRNE) places a strong emphasis on building and maintaining customer relationships to ensure the success of their business model. These relationships are essential in understanding customer needs, providing support, and fostering loyalty. Some key aspects of the company's customer relationships include:

• Engagement through patient advocacy groups: Sorrento Therapeutics actively engages with patient advocacy groups to gain insights into patient experiences, needs, and preferences. By listening to patients directly, the company can tailor its products and services to better meet their needs.
• Support services for healthcare providers: Sorrento Therapeutics offers robust support services for healthcare providers, including educational resources, training programs, and access to clinical experts. These services help healthcare providers better understand the company's products and how to incorporate them into patient care.
• Direct communication channels via professional seminars and webinars: The company utilizes professional seminars and webinars to directly engage with healthcare professionals, researchers, and other stakeholders. These events provide a platform for Sorrento Therapeutics to share the latest developments in their research and products and gather feedback from key audiences.
• Ongoing clinical support and education: Sorrento Therapeutics is committed to providing ongoing clinical support and education to healthcare professionals using their products. This includes regular updates on clinical trials, safety information, and best practices for product use.

Channels

Sorrento Therapeutics, Inc. utilizes a variety of channels to reach its target customers and distribute its pharmaceutical products:

• Direct Sales to Hospitals and Clinics: Sorrento Therapeutics has a dedicated sales team that directly sells its products to hospitals and clinics. This direct approach allows the company to build relationships with healthcare providers and ensure that its products are readily available to patients.
• Distribution through Pharmaceutical Networks: In addition to direct sales, Sorrento Therapeutics also partners with pharmaceutical networks to distribute its products. By leveraging existing distribution channels, the company is able to reach a wider audience and expand its market presence.
• Online Platforms for Professional Audience Engagement: Sorrento Therapeutics maintains an online presence through its website, social media channels, and email marketing campaigns. These platforms allow the company to engage with healthcare professionals, provide educational resources, and promote its products to a larger audience.
• Medical Conferences and Trade Shows: Sorrento Therapeutics actively participates in medical conferences and trade shows to showcase its products, network with healthcare professionals, and stay up-to-date on industry trends. These events provide valuable opportunities for the company to connect with key stakeholders and generate leads for potential partnerships.

Customer Segments

Sorrento Therapeutics, Inc. serves a variety of customer segments within the healthcare industry:

• These individuals are in need of effective treatments for their cancer diagnosis.
• Sorrento offers innovative therapies that may provide new hope and improved outcomes for these patients.

• Oncologists, nurses, and other healthcare professionals who specialize in cancer treatment are an important customer segment for Sorrento.
• These providers are looking for cutting-edge therapies that can benefit their patients and improve overall treatment outcomes.

• Companies involved in the distribution and retail of pharmaceutical products are key customers for Sorrento.
• These entities help bring Sorrento's therapies to market and ensure they reach the patients who need them.

• Academic institutions, research organizations, and other entities seeking to collaborate on groundbreaking research are another important customer segment for Sorrento.
• These partnerships can help Sorrento further develop and refine its therapies, leading to potential breakthroughs in cancer treatment.

By targeting these key customer segments, Sorrento Therapeutics, Inc. is able to effectively reach and serve the various stakeholders within the healthcare industry who can benefit from its innovative therapies.

Cost Structure

Sorrento Therapeutics, Inc. operates within a complex and multi-faceted cost structure to support its activities in the pharmaceutical and biotechnology industry. The company incurs various expenses to drive its operations, research, development, and commercialization efforts.

• R&D Expenditures: Sorrento Therapeutics allocates a significant portion of its budget towards research and development activities. This includes funding for the discovery of new therapies, development of drug candidates, and improvement of existing proprietary technologies.
• Clinical Trials and Regulatory Compliance: The company invests in conducting clinical trials to demonstrate the safety and efficacy of its products. Furthermore, Sorrento incurs costs related to ensuring compliance with regulatory requirements set by the FDA and other governing bodies.
• Marketing and Sales Expenses: As Sorrento progresses its drug candidates through the pipeline, it incurs costs associated with marketing and sales activities. This includes promoting products to healthcare providers, payers, and patients to drive adoption and market penetration.
• Operational Costs: Beyond research and clinical development, Sorrento faces operational expenses to support its day-to-day activities. This includes costs related to staffing, facility maintenance, utilities, and other general operating expenses.

Overall, Sorrento Therapeutics, Inc. maintains a comprehensive cost structure that reflects the demands of operating in the highly competitive and regulated pharmaceutical industry. By strategically managing these expenses, the company aims to maximize value creation for its stakeholders and achieve sustainable growth.

Revenue Streams

Sorrento Therapeutics, Inc. generates revenue through various streams that contribute to the overall sustainability and growth of the business. These revenue streams include:

• Sales of Proprietary Drugs and Therapies: The primary source of revenue for Sorrento Therapeutics is the sales of its proprietary drugs and therapies. These products are developed in-house and cater to a wide range of diseases and medical conditions. By offering these innovative solutions to patients and healthcare providers, Sorrento is able to generate significant revenue.
• Licensing Agreements for Patented Technologies: Another key revenue stream for Sorrento comes from licensing agreements for its patented technologies. Through these agreements, Sorrento grants other companies the right to use its proprietary technology in exchange for licensing fees and royalties. This not only generates immediate revenue but also establishes long-term partnerships in the industry.
• Revenue from Partnership and Collaboration Agreements: Sorrento Therapeutics collaborates with various pharmaceutical companies, research institutions, and healthcare organizations to develop and commercialize new products and technologies. These partnership agreements often involve joint research, development, and marketing efforts, with revenue sharing arrangements that benefit both parties involved.
• Grants and Funding from Research Projects: In addition to commercial activities, Sorrento also generates revenue through grants and funding from research projects. These grants support the company's ongoing research and development efforts, allowing Sorrento to explore new therapeutic options and expand its product pipeline.